Clinical and Developmental Immunology

Volume 2013 (2013), Article ID 430239, 13 pages

http://dx.doi.org/10.1155/2013/430239

Review Article

MicroRNAs Implicated in the Immunopathogenesis of Lupus Nephritis

Cristen B. Chafin¹ and Christopher M. Reilly1,2

¹Department of Biomedical Sciences & Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA

²Edward Via College of Osteopathic Medicine, Blacksburg, VA 24060, USA

Received 12 February 2013; Revised 20 May 2013; Accepted 12 June 2013

Academic Editor: Richard J. Quigg

Copyright © 2013 Cristen B. Chafin and Christopher M. Reilly. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the deposition of immune complexes due to widespread loss of immune tolerance to nuclear self-antigens. Deposition in the renal glomeruli results in the development of lupus nephritis (LN), the leading cause of morbidity and mortality in SLE. In addition to the well-recognized genetic susceptibility to SLE, disease pathogenesis is influenced by epigenetic regulators such as microRNAs (miRNAs). miRNAs are small, noncoding RNAs that bind to the 3′ untranslated region of target mRNAs resulting in posttranscriptional gene modulation. miRNAs play an important and dynamic role in the activation of innate immune cells and are critical in regulating the adaptive immune response. Immune stimulation and the resulting cytokine milieu alter miRNA expression while miRNAs themselves modify cellular responses to stimulation. Here we examine dysregulated miRNAs implicated in LN pathogenesis from human SLE patients and murine lupus models. The effects of LN-associated miRNAs in the kidney, peripheral blood mononuclear cells, macrophages, mesangial cells, dendritic cells, and splenocytes are discussed. As the role of miRNAs in immunopathogenesis becomes delineated, it is likely that specific miRNAs may serve as targets for therapeutic intervention in the treatment of LN and other pathologies.

1. Introduction

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the loss of immune tolerance to nuclear self-antigens. The deposition of autoantibodies along the glomerular basement membrane results in immune complex-mediated glomerulonephritis [1]. Mesangial cells, the primary immunoregulatory cells in the renal glomerulus, become activated due to the deposition of ICs. This recruits macrophages, B cells, T cells, and dendritic cells (DCs) to the kidney. Activated macrophages, mesangial cells, and DCs induce the maturation and activation of infiltrating T cells, which further activate macrophages and increase the B cell response [2]. Lupus nephritis (LN) is the major cause of morbidity and mortality in patients with SLE, affecting up to 70% of SLE patients [3]. Histological features include increased numbers of mesangial cells, overproduction of extracellular matrix, and inflammatory cell infiltration, which can lead to the development of sclerosis and fibrosis [4]. Depending on the severity of disease, 10–30% of LN patients will progress to end-stage renal failure [5].

It has been shown that genetic predisposition coupled with known and unknown environmental factors contributes to the development of SLE [6, 7]. Epigenetic defects have also been shown to play an important role in LN pathogenesis [8–10]. Epigenetics, which includes microRNA (miRNA) regulation, refers to stable and heritable changes in gene expression that alter the phenotype but not the underlying DNA sequence itself. miRNAs are small, non-coding RNAs that endogenously regulate gene expression by partially binding to the 3′ untranslated region (UTR) of target mRNAs [11–14]. miRNAs contribute to diverse physiological and pathophysiological functions including cell developmental timing, cell cycle control, apoptosis, and carcinogenesis [15, 16]. Hematopoiesis is fine-tuned by miRNAs at virtually every step [17]. In the last decade, increasing evidence has shown that miRNAs are critical not only for the regulation of immune cell development but also for modifying innate and adaptive immune responses [18].

A computational analysis performed on 72 lupus susceptibility genes in humans and mice revealed that most lupus susceptibility genes contain numerous target sites for over 140 conserved miRNAs. Three miRNAs (miR-181, miR-186, and miR-590-3p) are predicted to target over 50% of all lupus susceptibility genes [19]. Several studies have suggested that miRNAs play a role in the pathogenesis of LN by altering proinflammatory mediator production, innate immune cell responses, lymphocyte function, and Toll-like receptor (TLR) and NFκB signaling pathways [20–24]. For example, miRNAs can induce the expression of proinflammatory cytokines, dictating the magnitude and duration of the immune response [25, 26]. miRNA dysregulation can result from genetic variation, hormonal influences, environmental triggers, or even the proinflammatory environment itself [27]. Lipopolysaccharide (LPS) induces the expression of miRNAs and activates transcription factors that further regulate miRNA expression [28, 29]. LPS has been shown to induce the expression of several miRNAs including miR-9, miR-132, miR-146, miR-155, and miR-let-7a (let-7a) [30–33]. Dysregulated miRNA expression may represent an underlying trigger that induces multifactorial diseases such as SLE.

As pathogenic miRNAs are identified in LN pathogenesis, treatment strategies aimed at altering miRNA expression or signaling pathways may be employed to ameliorate disease pathogenesis in patients with SLE. Determining a patient’s miRNA expression profile from the blood or urine may allow the use of targeted therapies to specifically modulate abnormal miRNA expression patterns in individuals suffering from lupus. It has been well documented that lupus patients respond to immunosuppressive agents with varying degrees of efficacy [34]. This has presented a major challenge in selecting the most effective treatment option. Determining how particular therapeutics alter pathogenic miRNAs may ultimately provide a viable screening tool for specific, targeted therapy in SLE. In this review, we summarize the current data on miRNAs in the major immune cells as related to LN pathogenesis and examine the future directions in miRNA-based therapy for SLE.

2. miRNAs Broadly Implicated in Inflammatory Diseases

2.1. miR-21

miR-21 is induced upon inflammatory stimulation and is a key component of TLR, NFκB, and signal transducer and activator of transcription (STAT) signaling pathways [35–37]. The 3′ UTR of programmed cell death 4 (PDCD4) is a direct target of miR-21. PDCD4 is a proinflammatory protein that promotes NFκB activation and suppresses production of the anti-inflammatory cytokine IL-10. Overexpression of miR-21 in LPS-stimulated murine macrophages blocked NFκB activity, decreased PDCD4 production, and promoted the production of anti-inflammatory IL-10. PDCD4-deficient mice are protected from LPS-induced death, presumably by an IL-10-mediated reduction in NFκB activation [38].

miR-21 has been implicated in the immunopathogenesis of numerous inflammatory diseases [39]. Using an in vitro model of diabetes, Kato et al. showed that miR-21 overexpression in glucose-stimulated mesangial cells prevented cell proliferation by downregulating tumor suppressor phosphatase and tensin homolog (PTEN), whose 3′ UTR contains a binding site for miR-21 [40, 41]. miR-21 expression is induced by STAT3, a transcription factor activated by IL-6. miR-21 inhibition of PTEN leads to increased NFκB activation that is required to maintain the transformed state. miR-21, PTEN, NFκB, IL-6, and STAT3 are dynamic players in the positive feedback loop linking inflammation to cancer [35].

2.2. miR-146a

miR-146a may contribute to lineage determination in T cells as it is one of the only miRNAs that is differentially expressed in highly purified subsets of murine Th1 and Th2 cells [42]. Lu et al. demonstrated that miR-146a knockout mice develop a fatal immune-mediated disease similar to Foxp3 knockout mice that are devoid of functional Treg cells [43]. Although miR-146a knockout mice have increased Treg cells, their suppressive function is impaired. Treg cells without miR-146a (or Foxp3) acquire the ability to produce proinflammatory cytokines such as interferon-γ (IFN-γ). miR-146a deficiency in Treg cells caused an increase in STAT1 production, a key transcription factor required for Th1 effector cell differentiation. Because miR-146a regulates Treg cell suppressor function, the authors suggest that miR-146a maintains an optimal threshold of cytokine receptor-dependent activation of transcription factors that are necessary to suppress Th1 responses [43].

Since miR-146a has been reported to be an important negative regulator of acute responses during the activation of innate immunity, it has been suggested to play a regulatory role in the pathogenesis of SLE. miR-146a is induced by TLR activation (via LPS stimulation) and by proinflammatory mediators including tumor necrosis factor-α (TNF-α) and IFN-α [30]. miR-146a negatively regulates type I IFN production and myeloid differentiation factor 88 (MyD88) pathway activation induced by TLR stimulation [44]. Upon LPS-stimulated induction, miR-146a directly decreases TRAF6 and IRAK1 production, two signal transducers in the NFκB activation pathway whose 3′ UTRs contain multiple miR-146a target sequences [30, 45]. Therefore, miR-146a reduces or terminates the inflammatory response through a negative-feedback loop by downregulating TRAF6 and IRAK1.

Due to its importance in the control of inflammation, several studies have sought to determine if miR-146a-based therapy can improve disease outcome in lupus-prone animal models or human patients. It was recently shown that treatment with the anti-inflammatory drug calcitriol alters the expression of miR-146a in SLE patients. Sera miR-146a expression, which is downregulated in patients with SLE, was significantly increased in patients after treatment with calcitriol for 6 months [46, 47]. These findings suggest that the immunomodulatory effects exerted by calcitriol in patients with SLE may be due, in part, to alterations in miR-146a expression. In addition, sera levels of miR-146a may be used to monitor treatment response.

2.3. miR-155

Like miR-146a, miR-155 is vital to proper immune system functioning; it is highly expressed in Treg cells and is induced upon activation of T effector cells and myeloid cells [48, 49]. miR-155 is induced in macrophages in response to both bacterial and viral antigens, functions in the hematopoietic compartment to promote the development of inflammatory T cells, and is required for DC production of Th17-promoting cytokines [28, 50]. By developing miR-155-deficient mice, Rodriguez et al. found that miR-155 is required for the proper functioning of DCs, B cells, and T cells [51]. The DCs of miR-155-deficient mice were unable to effectively activate T cells, indicating a defect in antigen presentation or costimulatory function. As they aged, the lungs of miR-155-deficient mice showed increased airway remodeling due to the increased numbers of lymphocytes in bronchoalveolar lavage fluids. The authors noted that these changes are similar to the lung fibrosis that often complicates systemic autoimmune processes with lung involvement [51]. Zhou et al. examined the regulatory role of miR-155 in the regulation of plasmacytoid dendritic cell (pDC) activation and type I IFN production [52]. They found that miR-155 is upregulated upon TLR stimulation, providing another example of the link between stimulation, miRNA expression, and cellular activation. These studies show that miR-155 is broadly implicated in LN pathogenesis and dysregulated miR-155 expression may play various roles in pathophysiology by altering immune cell function [52].

3. LN-associated miRNAs in Tissues

3.1. Renal Tissue

miRNA expression profiles of renal tissue have gained much attention since Dai et al. provided a broad analysis of differentially expressed miRNAs in LN kidney biopsies [53]. They identified 36 upregulated and 30 downregulated miRNAs in LN renal tissue compared to healthy controls. Their previous studies had identified 16 differentially expressed miRNAs in the peripheral blood mononuclear cells (PBMCs) of SLE patients, none of which constituted any of the 66 miRNAs identified in SLE kidney biopsies. These studies suggest that miRNA expression patterns are cell and organ specific [53, 54].

Lupus rodent models have revealed miRNAs implicated in LN pathogenesis (Table 1). In the anti-Thy1.1 rodent model of glomerulonephritis, TGF-β and other cytokines and growth factors promote mesangial cell proliferation and activation, leading to mesangial proliferative glomerulonephritis [55]. Denby et al. identified 2 miRNAs (miR-21 and miR-214) that are induced upon transforming growth factor-β (TGF-β) stimulation in vitro and characterized them further using the anti-Thy1.1 rat model [56]. TGF-β-induced overexpression of miR-21 and miR-214 in tubular epithelial cells caused epithelial-mesenchymal transition- (EMT-) like changes characterized by decreased E-cadherin expression and increased α-smooth muscle actin (α-SMA) and collagen type I expression. These changes are characteristic of proliferating cells and tissue remodeling [57]. Blocking TGF-β downstream signaling in rat epithelial cells decreased the expression of miR-21 and miR-214 and prevented TGF-β-induced EMT by increasing E-cadherin expression and decreasing α-SMA and collagen type I expression. These results suggest that TGF-B-induced miR-21 and miR-214 expression may contribute to extracellular matrix production and mesangial proliferative glomerulonephritis [56].

Table 1: miRNAs implicated in LN pathogenesis.

Cell or tissue type
miR ID(s)
Origin
Strain
Expression
Results
Mechanism(s)
Reference

Renal
21 and 214
R
WKY (anti-Thy1.1)
↑
Expression is induced by TGF-β in tubular epithelial cells in vitro and in renal tissue in vivo
Unknown
[56]

Overexpression in tubular epithelial cells in vitro decreased E-cadherin expression and increased collagen type I and α-SMA expression
Unknown
[56]

146a
M
B6.MRLc1
↑
Increased expression positively correlated with IL-1β, IL-10, and CXCL expression, severe glomerular and interstitial lesions, and T cell and macrophage infiltration
Unknown
[59]

H
—
↑
Glomerular expression positively correlated with estimated GFR and histological activity index
Unknown
[60]

638
H
—
↑
Tubulointerstitial expression positively correlated with proteinuria and disease activity score
Unknown
[60]

PBMCs
21
H
—
↑
Strongly correlated with disease activity and activated T cells
Unknown
[23]

Inhibition in vitro reversed the activated T cell phenotype by increasing PDCD4 expression
The 3′ UTR of PDCD4 is a target of miR-21
[23]

125a
H
—
↓
Underexpression contributes to the elevated expression of RANTES (CCL5) in SLE, increasing T cell recruitment to inflammatory tissues
The 3′ UTR of the RANTES upstream regulator KFL13 is a target of miR-125a, indirectly increasing RANTES expression
[65]

145
H
—
↓
Decreased expression increased STAT1 expression in SLE patients
The 3′ UTR of STAT1 is a target of miR-145
[64]

146a
H
—
↓
Inversely correlated with disease activity and IFN-α/β scores
Unknown
[62]

Overexpression reduced the induction and downstream effects of type I IFN
The 3′ UTR of IRF5 and STAT1 are targets of miR-146a, reducing the induction of type I IFN
[62]

Promoter variant associated with SLE disease risk
SLE-associated SNP (rs57095329) decreases miR-146a expression levels
[63]

Positively correlated with GFR, CRP, and other renal function parameters; inversely correlated with proteinuria and SLEDAI
Unknown
[46]

155
H
—
↓
Positively correlated with GFR, CRP, and other renal function parameters
Unknown
[46]

224
H
—
↑
Increased expression accelerated T cell activation-induced cell death by suppressing API5 expression in SLE patients
The 3′ UTR of API5 is a target of miR-224
[64]

Mesangial cells
Let-7a
M
NZB/W
↑
Increased expression throughout the lifetime of NZB/W lupus mice; overexpression increased IL-6 expression and IL-6 production in vitro
The 3′ UTR of IL-6 is a target of let-7a; the exact mechanism of let-7a is unknown
[32]

Dendritic cells
155
H
—
↑
Induced by TLR stimulation after miR-155*; overexpression of miR-155 in normal pDCs significantly decreased IFN-α, IFN-β, and TNF-α expression
The 3′ UTR of the type I IFN regulator TAB2 is a target of miR-155, indirectly decreasing IFN-α and IFN-β
[52]

155*
H
—
↑
Induced by TLR stimulation before miR-155; overexpression of miR-155* in normal pDCs significantly increased IFN-α, IFN-β, and TNF-α expression
The 3′ UTR of the negative IFN regulator IRAKM is a target of miR-155*, indirectly increasing IFN-α and IFN-β
[52]

Splenocytes
15a
M
NZB/W
↑
Increased expression after disease was accelerated by IFN administration; differentially expressed in B cell subsets
Unknown
[69]

21
M
B6.Sle123
↑
Inhibition increased PDCD4 expression in T cells and reversed splenomegaly, improving overall disease outcome
The 3′ UTR of PDCD4 is a target of miR-21
[70]

M and H
MRL-lpr
↑
Downregulated DNMT1 expression in T cells
The 3′ UTR of the DNMT1 upstream regulator RASGRP1 is a target of miR-21, indirectly downregulating DNMT1
[71]

126
H
—
↑
Overexpression contributes to T cell autoreactivity by decreasing DNMT1 expression
The 3′ UTR of DNMT1 is a target of miR-126
[72]

Overexpression in healthy donors was sufficient for T cell autoreactivity and B cell hyperstimulation, while inhibition in SLE patients resulted in T and B cell inactivation
Unknown
[72]

142-3p and 142-5p
H
—
↓
Underexpressed in SLE CD4⁺ T cells
Dysregulated DNA and histone methylation of the miR-142 promoter
[73]

Underexpression in CD4⁺ T cells increased production of CD84, IL-10, and SAP
The 3′ UTR of CD84 and IL-10 are targets of miR-142-3p; the 3′ UTR of SAP is a target of miR-142-5p
[73]

Inhibition in healthy donor CD4⁺ T cells caused T cell overactivation and B cell hyperstimulation, while overexpression in SLE CD4⁺ T cells had the opposite effect
Although CD84 and SAP stimulate T-B cell interactions, the exact mechanism of miR-142 is unknown
[73]

146a
M
MRL/lpr
↑
Increased expression associated with disease development
Unknown
[74]

148a
M and H
MRL/lpr
↑
Downregulated DNMT1 expression in T cells
The protein coding region of the DNMT1 transcript is a target of miR-148a
[71]

Induced overexpression of autoimmune-associated, methylation-sensitive genes in CD4⁺ T cells including CD70 and LFA-1
Inhibition of DNMT1 results in DNA hypomethylation and the overexpression of methylation-sensitive genes
[71]

155
M
MRL/lpr, NZB/W
↑
Increased expression associated with disease development
Unknown
[74]

Abbreviations: H: human; M: mouse; R: rat.

↑: increased expression; ↓: decreased expression.

α-SMA: α-smooth muscle actin; API: apoptosis inhibitory protein; CRP: C-reactive protein; DNMT: DNA methyltransferase; GFR: glomerular filtration rate; IFN: interferon; IL: interleukin; IRAK: IL-1 receptor-associated kinase, IRF: interferon regulatory factor; NZB/W: New Zealand Black/White; PBMCs: peripheral blood mononuclear cells; pDC: plasmacytoid dendritic cell; SNP: single-nucleotide polymorphism; PDCD: programmed cell death; SLE: systemic lupus erythematosus; SLEDAI: SLE Disease Associated Index; STAT: signal transducer and activator of transcription; TGF-β: transforming growth factor-β; TTP: tristetraprolin.

miRNAs that contribute to inflammation in chronic kidney disease (CKD) were recently examined in the B6.MRLc1 model, a congenic strain carrying a region of chromosome 1 derived from MRL/MpJ mice that develop IC-mediated glomerulonephritis [58]. miR-146a expression was found to be significantly increased in B6.MRLc1 kidneys compared to healthy controls. B6.MRLc1 mice that expressed high levels of miR-146a expression showed severe glomerular and interstitial lesions including cell infiltration, tubular atrophy, and interstitial fibrosis. The lesions had increased macrophage and T cell infiltration as well as increased expression of cell-specific mRNAs associated with the development of renal lesions (CD68 and S100a4 for macrophages and fibroblasts, resp.) [59]. miR-146a expression was also positively correlated with IL-1β, IL-10, and CXCL expression. Because miR-146a is increased in the kidneys of B6.MRLc1 mice and continues to increase as they age, this model may be predisposed to increased miR-146a expression that initiates and perpetuates renal inflammation [59].

Research by Lu et al. confirmed that miR-146a is upregulated in glomerular tissue from LN patients and found that miR-146a is not overexpressed in LN tubulointerstitial tissue [60]. miR-638 expression, on the other hand, was underexpressed in glomerular tissue but higher in tubulointerstitial tissue. Glomerular expression of miR-146a positively correlated with both estimated glomerular filtration rate (GFR) and histological activity index, determined from the sum of semiquantitative scores of inflammation parameters [61]. Increased tubulointerstitial expression of miR-638 was positively correlated with proteinuria and SLE Disease Activity Index (SLEDAI) score. While the correlation between changes in miRNA expression and clinical disease severity suggests that these miRNAs may play a role in the pathogenesis of LN, it is currently unknown whether changes in miR-638 expression are pathogenic or an epiphenomenon [60].

3.2. PBMCs

While miR-146a was not initially reported to be decreased in SLE PBMCs, other miRNA expression screenings have revealed that miR-146a is significantly decreased in SLE patients and is inversely correlated with SLEDAI and IFN-α/β scores in SLE patients [46, 54, 62]. Furthermore, in vitro studies by Tang et al. revealed that overexpression of miR-146a reduced type I IFN induction in PBMCs [62]. They found that miR-146a negatively regulates both type I IFN production and TLR-stimulated downstream pathway activation by targeting the 3′ UTR of interferon regulatory factor-5 (IRF5) and STAT1, key components in the type I IFN signaling cascade. The authors concluded that miR-146a deficiency is one of the causal factors in the abnormal activation of the type I IFN pathway in SLE [62].

A follow-up study identified a functional variant in the promoter of miR-146a that is associated with SLE disease risk; the promoter mutation resulted in decreased binding to the transcription factor ETS-1. Intriguingly, genomewide association studies have identified an association between SLE risk and a functional variant of ETS1. The researchers observed additive effects of the risk alleles of miR-146a and ETS1, which suggests that individuals with 2 or more of these alleles are at a greater risk of developing SLE than those carrying only one allele [63].

Stagakis et al. identified 27 differentially expressed miRNAs in the PBMCs of SLE patients, 2 of which corresponded with the miRNAs identified by Dai et al. and 19 of which correlated with disease activity [23, 54]. Of these disease-correlated miRNAs, eight were differentially expressed in T cells and 4 in B cells. Upregulation of miR-21 strongly correlated with disease activity and activated T cells; inhibition of miR-21 reversed the activated T cell phenotype by increasing PDCD4 expression [23]. Another recent study found 7 abnormally expressed miRNAs (miR-145, miR-224, miR-150, miR-483-5p, miR-513-5p, miR-516a-5p, and miR-629) in SLE T cells compared to healthy controls. In a larger follow-up study, underexpression of miR-145 was confirmed and increased levels of STAT1, a target of miR-145, were observed in SLE T cells compared to healthy controls. Overexpression of miR-224 and decreased expression levels of its target, apoptosis inhibitory protein 5 (API5), were also confirmed. T cells transfected with miR-224 in vitro were more susceptible to activation-induced apoptosis, indicating that SLE T cells overexpressing miR-224 may have an intrinsic defect that causes accelerated cell activation-induced apoptosis [64].

An additional study examining PBMC miRNAs found that decreased miR-125a expression in SLE patients contributed to increased KLF13 production by T cells. miR-125a has binding sites in the 3′ UTR of KLF13, which belongs to the family of transcription factors that regulates the expression of the inflammatory chemokine RANTES (CCL5) in T cells. Increased RANTES expression is associated with persistent or recurrent organ inflammation due to its recruitment of T cells to inflammatory tissues. Increasing miR-125a levels in T cells from SLE patients ex vivo alleviated elevated RANTES expression. This study confirmed that underexpression of miR-125a contributes to the elevated expression of RANTES in SLE, increasing T cell recruitment to inflammatory tissues [65].

4. LN-associated miRNAs in Innate Immune Cells

The innate immune response provides the initial defense against infection by external pathogens and is predominantly mediated by macrophages, DCs, and neutrophils. The presence of pathogens is commonly detected by macrophage and DC TLRs that bind conserved microbial products, triggering downstream signaling pathways to initiate inflammatory responses [66]. Through TLR activation, ICs from lupus patients induce pDCs to secrete type I IFN [67]. Activated DCs induce maturation and activation of infiltrating T cells, which further activates macrophages and increases the B cell response. The innate immune response, in particular DCs, promotes the activation of the adaptive immune system [68]. Since miRNAs are critical for modifying innate and adaptive immune responses, dysregulated miRNA expression may represent an underlying cause to LN pathogenesis (Table 1).

4.1. Macrophages/Mesangial Cells

miRNA expression is directly and indirectly altered after TLR activation and regulates macrophage signaling pathways that lead to the secretion of proinflammatory cytokines [28, 31, 75]. Let-7a and miR-147 are directly induced upon LPS stimulation due to NFκB binding sites in their promoter regions, which induces the expression of proinflammatory cytokines including TNF-α and IL-6 [29, 75]. TNF-α, a critical cytokine involved in the response to LPS stimulation, increases miR-155 expression via JNK pathway activation, further increasing TNF-α production [28, 76, 77]. Inhibition of JNK blocks the induction of miR-155, demonstrating that upregulated miR-155 expression in LPS-stimulated macrophages is indirectly due to JNK pathway activation [31, 75]. These well-defined positive feedback loops demonstrate that stimulation-dependent miRNA expression induces cytokine production that further activates cells, which continues to alter miRNA expression.

Mesangial cells, the primary immunoregulatory cells resident to the renal glomerulus, possess phagocytic and contractile properties. Regulatory mechanisms of mesangial cells include a complex array of factors that control cell proliferation, survival, apoptosis, and GFR. Mesangial cells from LN patients and lupus-prone mice have a heightened response to inflammatory stimulation [78, 79]. Mesangial cells from NZB/W mice have been shown to produce significantly more chemokines in response to LPS stimulation than controls [80]. Kato et al. demonstrated the involvement of miRNAs in mesangial cell activation [41]. They determined that TGF-β activates Akt in glomerular mesangial cells by inducing miR-215a and miR-217, revealing a role for miRNAs in kidney disorders. We recently found that let-7a expression was significantly increased in the mesangial cells of prediseased and actively diseased New Zealand Black/White (NZB/W) mice compared to age-matched New Zealand White (NZW) mice. Using in vitro techniques, we demonstrated that let-7a has a key role in regulating IL-6. Overexpression of let-7a increased IL-6 production in stimulated mesangial cells compared to nontransfected controls. Increased let-7a expression in the prediseased and diseased state may contribute to the increase in IL-6 production in young and old NZB/W mice. These data suggest that increased let-7a expression may predispose lupus mice to increased inflammatory mediator production with immune stimulation [32].

4.2. Dendritic Cells

Another significant immune cell that contributes to immunity in complex ways is the dendritic cell. DCs are widely considered to be critical for activating T cell responses, promoting B cell antibody production, and secreting cytokines in response to infections [81]. In these ways they may direct autoimmunity and tolerance by serving as the primary antigen presenting cells (APCs) to initiate T cell autoimmunity, promoting B cell autoantibody production, and secreting proinflammatory cytokines. Altered function of DCs is known to play a major role in the development of autoimmunity [82]. A recent study examining the functional characteristics of DCs in lupus patients found a significant increase in the percentage of cytokine-producing DCs in addition to an increase in the amount of cytokine per cell in SLE patients compared with healthy subjects [83]. pDCs are a specialized subset of DCs that are very active in IFN-α production, which promotes B cell differentiation into antibody-producing plasma cells (among many other functions). LN patients have been shown to have increased numbers of pDCs in the kidney as well as sustained IFN-α production [84].

The importance of TLR-induced miRNA expression in the regulation of pDC activation and type I IFN production has been examined. miR-155 and miR-155* (the complementary passenger strand in the miRNA duplex) were found to be the most strongly induced miRNAs in pDCs and were also differentially induced over time. The investigators found that miR-155* is induced before miR-155 and has biological activity. miR-155* induction after TLR stimulation increases IFN-α production by targeting IRAKM, which negatively regulates the TLR pathways by preventing the dissociation of IRAK1 and IRAK4 from MyD88 and the formation of IRAK1/TRAF6 complexes. The continual increase in miR-155 expression resulted in a reduction in IFN-α due to the targeting of TAB2 by miR-155. TAB2 regulates type I IFN production in pDCs upon TLR stimulation. Taken together, these results suggest that there is cooperative involvement of both strands of the miRNA duplex in pDC activation [52].

5. LN-associated miRNAs in Adaptive Immune Cells

miRNAs were shown to be essential for altering the adaptive immune response in studies that conditionally depleted the enzyme Dicer from T or B cells. Dicer cleaves pre-miRNAs into double-stranded RNA products (duplexes) once they reach the cytoplasm [85]. T cell Dicer depletion indicated that miRNAs regulate diverse aspects of T cell biology, including basic cellular processes such as proliferation and survival as well as cell lineage decisions and cytokine production during T helper cell differentiation [86]. Dicer depletion in B cells resulted in the complete developmental block of B cells in the pro- to pre-B cell transition, affecting antibody diversity. These results indicate that miRNAs are critical for modifying adaptive immune responses and that irregular miRNA expression may represent an underlying cause to LN pathogenesis (Table 1) [87].

5.1. Splenocytes

Although many miRNAs are expressed in T cell subsets, one study found 7 miRNAs (miR-16, miR-21, miR-142-3p, miR-142-5p, miR-150, miR-15b, and let-7f) account for almost 60% of all T cell miRNAs. These miRNAs (except for miR-21) were downregulated in effector T cells compared to naïve cells. Memory T cell expression was similar to the expression seen in naïve T cells. miR-21 expression was higher in effector and memory T cells compared to naïve T cells, indicating that miRNAs are differentially expressed in hematopoietic lineages. These results suggest that miRNAs may contribute dynamically to cell differentiation and the maintenance of cell identity [88].

It has recently been demonstrated that murine lupus models share a common disease-associated miRNA expression pattern despite strain differences in lupus susceptibility loci and clinical manifestation. In the MRL/lpr model, miR-146a was associated with disease development due to increased expression in splenocytes from 3-4-month-old mice compared to 1-month-old mice. miR-155 was found to be associated with disease development in both the MRL/lpr and the NZB/W models [74]. An additional study investigated the relationship between IFN-accelerated disease, miRNAs, and B cell subsets in NZB/W mice due to the acceleration of disease by type I IFN in this model. Splenic and plasma miR-15a levels were elevated in diseased mice compared to prediseased mice. Increased autoantibody levels were significantly correlated with increased miR-15a expression. The immunosuppressive B cell subset (B-10) was reduced following IFN treatment, yet it had the highest miR-15a expression that increased with disease development. miR-15a expression in the pathogenic B cell subset (B-2) only increased upon disease onset. Although it is currently unknown whether changes in miR-15a expression are pathogenic or an epiphenomenon, these results suggest that miR-15a is implicated in the development of SLE in NZB/W mice by directing the balance of splenic B cell subsets [69].

Pathogenic miRNAs have also been examined in the lymphocytes of B6.Sle123 mice. These mice spontaneously develop autoimmune disease characterized by autoantibodies, splenomegaly, and IC-mediated glomerulonephritis. They also have elevated ratios of CD4⁺ to CD8⁺ T cells. The expression of miR-21, which is upregulated in SLE T cells and has been shown to regulate apoptosis and cell proliferation pathways in part by targeting PDCD4, was found to be upregulated in B6.Sle123 splenocytes [23, 70]. Short-term inhibition of miR-21 in vivo resulted in an approximate 20% decrease in PDCD4 expression in naïve CD4⁺ T cells compared to T cells from control mice. Long-term inhibition of miR-21 in vivo significantly reduced splenomegaly in B6.Sle123 mice compared to the controls. In addition, the number of Fas receptor-expressing splenic B cells and the CD4⁺ to CD8⁺ T cell ratio were reduced, which suggests that miR-21 inhibition skews the T cell ratio towards that of the non-autoimmune strain [70].

The overexpression of miR-148a has also been investigated in CD4⁺ T cells from patients with lupus as well as lupus-prone mice. Due to the importance of DNA methylation abnormalities in SLE pathogenesis, Pan et al. examined the roles of mir-21 and miR-148a in aberrant CD4⁺ T cell DNA hypomethylation [71]. miR-21 and miR-148a downregulated DNA methyltransferase 1 (DNMT1) expression in vitro and in vivo, decreasing DNMT1 production in T cells. Downregulation of DNMT1 in CD4⁺ T cells contributes to lupus autoreactivity by inducing T cell DNA hypomethylation; this results in the overexpression of autoimmunity-associated genes including lymphocyte function-associated antigen 1 (LFA-1 or CD11a) and CD70 [89]. While a putative miR-148a binding site has been predicted in the 3′ UTR of DNMT1, there are no predicted binding sites for miR-21. The researchers discovered that miR-21 indirectly downregulated DNMT1 expression by targeting its upstream regulator in the Ras-MAPK pathway, RASGRP1. Intriguingly, miR-148a directly downregulated DNMT1 expression by targeting the protein coding region of its transcript. In addition, miR-21 and miR-148a induced the overexpression of methylation-sensitive, autoimmune-associated genes in CD4⁺ T cells including CD70 and LFA-1. Furthermore, the investigators found that the effects were reversed when inhibitors of either miR-21 or miR-148a were transfected into CD4⁺ T cells isolated from SLE patients, implying that hypomethylation in CD4⁺ T cells can potentially be alleviated by inhibiting these miRNAs [71].

Another posttranscriptional modifier of DNMT1, miR-126, was found to be overexpressed in CD4⁺ T cells from SLE patients [72]. Its degree of overexpression negatively correlated with DNMT1 protein levels. In addition, the expression of miR-142-3p and miR-142-5p was reduced to less than half in SLE CD4⁺ T cells compared to CD4⁺ T cells from healthy controls. miR-126, miR-142-3p, and miR-142-5p are predicted to target genes associated with SLE, which implicates their aberrant expression in CD4⁺ T cells in LN pathogenesis. Overexpression of miR-126 in primary CD4⁺ T cells from SLE patients contributed to T cell autoreactivity by targeting DNMT1, while inhibition in SLE patients resulted in T and B cell inactivation. Overexpression of miR-126 in primary CD4⁺ T cells from healthy donors resulted in the demethylation and upregulation of autoimmunity-associated genes including CD11a and CD70, inducing T cell and B cell hyperactivity. These results demonstrate that overexpression of miR-126 can aberrantly induce splenocyte activity towards that of an autoimmune phenotype [72].

Decreased expression of miR-142-3p and miR-142-5p in SLE CD4⁺ T cells was confirmed in studies by Ding et al. [73]. CD84 and IL-10 are predicted targets of miR-142-3p, while signaling lymphocytic activation molecule-associated protein (SAP) is a potential target of miR-142-5p. When miR-142-3p was inhibited in CD4⁺ T cells from healthy donors, protein levels of CD84 and IL-10 increased. SAP protein production was decreased after inhibition of mir-142-5p. Inhibition in healthy donor CD4⁺ T cells caused T cell overactivation and B cell hyperstimulation. These results were reversed after transfection of the corresponding miRNA mimic. Overexpression in SLE CD4⁺ T cells decreased CD40L, inducible T cell costimulator (ICOS), IL-4, IL-10, and IL-21 protein levels, reduced T cell proliferation, and reduced IgG production compared to controls. These results indicate that reduced expression of miR-142-3p and miR-142-5p in CD4⁺ T cells of SLE patients contributes to T cell hyperactivity and B cell hyperstimulation [73].

6. Future Directions in LN Treatment

miRNAs are being recognized as potential therapeutic targets in the treatment of LN and other diseases as increasing numbers are identified as specific disease-modifying agents and not merely disease correlates. Recent studies have shown that exogenously increasing let-7a, a well-known tumor suppressor that is downregulated in many types of cancer, is effective in treating tumorigenesis by decreasing cell migration, invasion, and proliferation in vitro and in vivo [90–94]. Intranasal let-7 administration reduced lung tumor formation in a murine model of lung cancer [95]. Tumorigenesis was suppressed in murine gastric cancer cells in vivo by overexpression of let-7a, which decreased cell proliferation by causing G₁ arrest [96].

Lupus therapeutics have recently been recognized for their ability to alter miRNA expression levels [97, 98]. Once disease-associated miRNA expression is determined in patients with SLE, tailored therapies can be designed using immunosuppressant treatments that alter pathologic miRNAs. Examining miRNA expression profiles during the course of immunosuppressant therapy may more accurately assess treatment responsiveness. Since lupus susceptibility genes contain target sites for various miRNAs, future treatments may target multiple disease-associated miRNAs that synergistically contribute to LN pathogenesis. Additionally, pathogenic miRNA expression may be used to assess treatment feasibility. This will allow the use of targeted therapies to specifically modulate abnormal miRNA expression patterns in individuals suffering from lupus.

Circulating miRNAs have been used as diagnostic markers in the treatment and diagnosis of certain cancers [99, 100]. Since the discovery of dysregulated miRNA expression in the serum and urine of SLE patients, the interest in using miRNAs as noninvasive biomarkers has increased [54, 97]. One of the many advantages of using miRNAs as disease biomarkers is the availability of highly sensitive PCR detection methods and their low complexity compared with protein biomarkers [101]. In addition, pathogenic miRNAs may be able to detect early SLE disease onset before clinical, pathological findings arise. Assessing miRNA expression in different tissues may alter our organ-specific and systemic understanding of SLE. For example, detecting alterations in urinary miRNA expression may offer valuable information regarding changes in the glomerular microenvironment, while pathogenic alterations in PBMCs may reveal the global state of the SLE patient.

6.1. Therapeutic Modulation of miRNAs

Because of the vast and critical roles miRNAs perform in fundamental immune processes (and due to their dysregulated expression in many pathological conditions), they have become an increasingly attractive target for therapeutic modulation. While the endogenous delivery of miRNAs has had limited testing in vivo, the risk of altering unintentional targets remains high as a single miRNA can have multiple gene targets and these targets can have profound effects on a variety of miRNAs [102–104]. The solution to this potential problem may lie in targeting miRNAs broadly associated with SLE such as miR-146a [42, 60, 62, 74, 105]. Pan et al. therapeutically altered miR-146a levels using virus-like particles (VLPs) containing miR-146a, which were delivered via tail vein injection to lupus-prone BXSB mice [106]. After administration of the miR146a-containing VLPs, high levels of miR-146a were detected in PBMCs, lung, spleen, and kidney tissues from BXSB and control mice. miR-146a therapy significantly reduced autoantibody, IFN-α, IL-1β, IL-6, and total IgG production. Widespread restoration of miR-146a by VLPs was effective in ameliorating SLE progression in lupus-prone mice, providing a potential novel therapy for SLE treatment [106].

While the initial findings from studies that systemically increase miRNA levels are promising, a more effective treatment may utilize targeted delivery systems. A novel approach to manipulating mesangial miRNA expression alone could be employed by targeting the mesangial cell surface marker that is unique to the kidney glomeruli: Integrin α8 [107]. Scindia et al. revealed that this molecule can be used to effectively target immunoliposomes to mesangial cells by tail vein injection [108]. pDCs also possess a unique cellular marker: plasmacytoid dendritic cell antigen (PDCA) [109]. In this way, pDCs may be specifically targeted instead of all splenocytes or PBMCs, considering that a miRNA may not be differentially expressed in other cell types found in the spleen or peripheral blood. For example, while miR-146a is decreased in PBMCs, it is upregulated in murine Th1 cells compared to naïve T cells and Th2 cells [62, 110].

6.2. Tailored Therapy Based on the Patient’s miRNA Profile

Although glucocorticoids are the first-line treatment for a wide range of autoimmune diseases, up to 30% of patients with SLE are steroid resistant, demonstrating persistent tissue inflammation despite treatment with high doses of steroids [111, 112]. Disease-associated miRNAs may become unique biomarkers that help determine the course of the patient’s immunosuppressant therapy. The use of miRNAs as selection markers for disease treatment is underway in the treatment of ovarian cancer. Researchers found that let-7a expression was predictive of a patient’s outcome after chemotherapy; let-7a expression differed substantially between the patients who did or did not respond to chemotherapy containing platinum and paclitaxel. The survival of patients with low let-7a expression was higher when they received platinum and paclitaxel in combination; patients with high let-7a expression did not have improved survival after adding paclitaxel to platinum-based therapy [113].

If disease-associated miRNAs are targeted, the treatment of SLE could be greatly improved. Steroid-resistant patients, amongst others, may benefit from tailored immunotherapy. Revealing miRNAs with therapeutic potential may provide insight in treating other inflammatory diseases as well. Polikepahad et al. showed that the inhibition of let-7 miRNAs in an experimental model of asthma in vivo profoundly inhibited the production of allergic cytokines and the disease phenotype, indicating that let-7a may be a potential therapeutic target in other diseases as well [114].

7. Conclusion

miRNAs are now recognized as key regulators of gene expression. A single miRNA, or even multiple miRNAs, may contribute to cell development and immunoregulation in diverse ways. Increasing evidence has shown that miRNAs are not only critical for the regulation of immune cell development but also for modifying innate and adaptive immune responses. Evidence suggests that miRNAs are involved in LN pathogenesis by altering innate immune cell responsiveness, lymphocyte function, proinflammatory mediator production, and TLR and NFκB signaling pathways.

Increasing evidence indicates that dysregulated miRNA expression in specific cell types contributes to LN immunopathogenesis. While it is becoming clear that miRNAs modulate components of inflammatory signaling cascades, it is not fully understood how miRNAs are regulated by different cell types in SLE. Overall, the possibility of altering miRNA expression in order to ameliorate disease remains promising. Studies that alter pathogenic miRNAs have shown that miRNA-based therapies have the potential for becoming therapeutic tools for the treatment of SLE and other diseases. As we learn more about the intricacies of miRNAs and epigenetics, targets for drug development will continue to emerge.

Abbreviations

H: | Humans
M: | Mice
R: | Rats
↑: | Increased expression
↓: | Decreased expression
α-SMA: | α-Smooth muscle actin
API: | Apoptosis inhibitory protein
CRP: | C-Reactive protein
DNMT: | DNA methyltransferase
GFR: | Glomerular filtration rate
IFN: | Interferon
IL: | Interleukin
IRAK: | IL-1 receptor-associated kinase
IRF: | Interferon regulatory factor
NZB/W: | New Zealand Black/White
PBMCs: | Peripheral blood mononuclear cells
pDC: | Plasmacytoid dendritic cell
SNP: | Single-nucleotide polymorphism
PDCD: | Programmed cell death
SLE: | Systemic lupus erythematosus
SLEDAI: | SLE Disease Associated Index
STAT: | Signal transducer and activator of transcription
TGF-β: | Transforming growth factor-β
TTP: | Tristetraprolin.

Acknowledgment

This work was supported by a Grant from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (R15 AR062883).

References

J. C. Oates and G. S. Gilkeson, “Mediators of injury in lupus nephritis,” Current Opinion in Rheumatology, vol. 14, no. 5, pp. 498–503, 2002.

G. Seret, Y. le Meur, Y. Renaudineau, and P. Youinou, “Mesangial cell-specific antibodies are central to the pathogenesis of lupus nephritis,” Clinical & Developmental Immunology, vol. 2012, Article ID 579670, 8 pages, 2012.

S. Yung and T. M. Chan, “Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown,” Clinical & Developmental Immunology, vol. 2012, Article ID 139365, 13 pages, 2012.

E. J. Lewis and M. M. Schwartz, “Pathology of lupus nephritis,” Lupus, vol. 14, no. 1, pp. 31–38, 2005.

A. A. Aran and C. Putterman, “Treatment of lupus nephritis: facing the era of immunotherapy,” Panminerva Medica, vol. 50, no. 3, pp. 235–245, 2008.

A. Delgado-Vega, E. Sanchez, S. Lofgren, C. Castillejo-Lopez, and M. E. Alarcon-Riquelme, “Recent findings on genetics of systemic autoimmune diseases,” Current Opinion in Immunology, vol. 22, no. 6, pp. 698–705, 2010.

G. Zandman-Goddard, M. Solomon, Z. Rosman, E. Peeva, and Y. Shoenfeld, “Environment and lupus-related diseases,” Lupus, vol. 21, no. 3, pp. 241–250, 2012.

N. Hu, X. Qiu, Y. Luo, J. Yuan, Y. Li, W. Lei, et al., “Abnormal histone modification patterns in lupus CD4+ T cells,” Journal of Rheumatology, vol. 35, no. 5, pp. 804–810, 2008.

C. L. Liu, S. Tangsombatvisit, J. M. Rosenberg, G. Mandelbaum, E. C. Gillespie, O. P. Gozani, et al., “Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies,” Arthritis Research & Therapy, vol. 14, no. 1, article R25, 2012.

M. A. Jeffries and A. H. Sawalha, “Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents,” International Journal of Clinical Rheumatology, vol. 6, no. 4, pp. 423–439, 2011.

L. He and G. J. Hannon, “MicroRNAs: small RNAs with a big role in gene regulation,” Nature Reviews Genetics, vol. 5, no. 7, pp. 522–531, 2004.

D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.

B. N. Davis-Dusenbery and A. Hata, “Mechanisms of control of microRNA biogenesis,” Journal of Biochemistry, vol. 148, no. 4, pp. 381–392, 2010.

V. N. Kim, J. Han, and M. C. Siomi, “Biogenesis of small RNAs in animals,” Nature Reviews Molecular Cell Biology, vol. 10, no. 2, pp. 126–139, 2009.

J. T. Mendell, “MicroRNAs: critical regulators of development, cellular physiology and malignancy,” Cell Cycle, vol. 4, no. 9, pp. 1179–1184, 2005.

G. A. Calin and C. M. Croce, “MicroRNA signatures in human cancers,” Nature Reviews Cancer, vol. 6, no. 11, pp. 857–866, 2006.

U. Bissels, A. Bosio, and W. Wagner, “MicroRNAs are shaping the hematopoietic landscape,” Haematologica, vol. 97, no. 2, pp. 160–167, 2012.

E. Tili, J. J. Michaille, and G. A. Calin, “Expression and function of micro-RNAs in immune cells during normal or disease state,” International Journal of Medical Sciences, vol. 5, no. 2, pp. 73–79, 2008.

C. G. Vinuesa, R. J. Rigby, and D. Yu, “Logic and extent of miRNA-mediated control of autoimmune gene expression,” International Reviews of Immunology, vol. 28, no. 3-4, pp. 112–138, 2009.

M. P. Gantier, A. J. Sadler, and B. R. Williams, “Fine-tuning of the innate immune response by microRNAs,” Immunology and Cell Biology, vol. 85, no. 6, pp. 458–462, 2007.

R. Dai and S. A. Ahmed, “MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases,” Translational Research, vol. 157, no. 4, pp. 163–179, 2011.

S. Zhao, Y. Wang, Y. Liang, M. Zhao, H. Long, S. Ding, et al., “MicroRNA-126 regulates DNA methylation in CD4(+) T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1,” Arthritis & Rheumatism, vol. 63, no. 5, pp. 1376–1386, 2011.

E. Stagakis, G. Bertsias, P. Verginis et al., “Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression,” Annals of the Rheumatic Diseases, vol. 70, no. 8, pp. 1496–1506, 2011.

S. W. Kim, K. Ramasamy, H. Bouamar, A. P. Lin, D. Jiang, and R. C. Aguiar, “MicroRNAs miR-125a and miR-125b constitutively activate the NF-kappaB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20),” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 20, pp. 7865–7870, 2012.

F. Ma, X. Liu, D. Li et al., “MicroRNA-466l upregulates IL-10 expression in TLR-triggered macrophages by antagonizing RNA-binding protein tristetraprolin-mediated IL-10 mRNA degradation,” Journal of Immunology, vol. 184, no. 11, pp. 6053–6059, 2010.

A. J. Asirvatham, W. J. Magner, and T. B. Tomasi, “miRNA regulation of cytokine genes,” Cytokine, vol. 45, no. 2, pp. 58–69, 2009.

K. U. Tufekci, M. G. Oner, S. Genc, and K. Genc, “MicroRNAs and multiple sclerosis,” Autoimmune Diseases, vol. 2011, Article ID 807426, 27 pages, 2011.

E. Tili, J.-J. Michaille, A. Cimino et al., “Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock,” Journal of Immunology, vol. 179, no. 8, pp. 5082–5089, 2007.

D. J. Wang, A. Legesse-Miller, E. L. Johnson, and H. A. Coller, “Regulation of the let-7a-3 promoter by NF-kappaB,” Plos One, vol. 7, no. 2, article e31240, 2012.

K. D. Taganov, M. P. Boldin, K. J. Chang, and D. Baltimore, “NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 33, pp. 12481–12486, 2006.

R. M. O'Connell, K. D. Taganov, M. P. Boldin, G. Cheng, and D. Baltimore, “MicroRNA-155 is induced during the macrophage inflammatory response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 5, Article ID 061073, pp. 1604–1609, 2007.

C. B. Chafin, N. L. Regna, R. Dai, D. L. Caudell, and C. M. Reilly, “MicroRNA-let-7a expression is increased in the mesangial cells of NZB/W mice and increases IL-6 production in vitro,” Autoimmunity. In press

F. Bazzoni, M. Rossato, M. Fabbri, D. Gaudiosi, M. Mirolo, L. Mori, et al., “Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 13, pp. 5282–5287, 2009.

G. B. Appel, “New and future therapies for lupus nephritis,” Cleveland Clinic Journal of Medicine, vol. 79, no. 2, pp. 134–140, 2012.

D. Iliopoulos, S. A. Jaeger, H. A. Hirsch, M. L. Bulyk, and K. Struhl, “STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer,” Molecular Cell, vol. 39, no. 4, pp. 493–506, 2010.

S. R. Quinn and L. A. O'Neill , “A trio of microRNAs that control Toll-like receptor signalling,” International Immunology, vol. 23, no. 7, pp. 421–425, 2011.

D. Iliopoulos, H. A. Hirsch, and K. Struhl, “An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation,” Cell, vol. 139, no. 4, Article ID 278382, pp. 693–706, 2009.

F. J. Sheedy, E. Palsson-Mcdermott, E. J. Hennessy et al., “Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21,” Nature Immunology, vol. 11, no. 2, pp. 141–147, 2010.

R. Kumarswamy, I. Volkmann, and T. Thum, “Regulation and function of miRNA-21 in health and disease,” RNA Biology, vol. 8, no. 5, pp. 706–713, 2011.

F. Meng, R. Henson, M. Lang et al., “Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines,” Gastroenterology, vol. 130, no. 7, pp. 2113–2129, 2006.

M. Kato, S. Putta, M. Wang et al., “TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN,” Nature Cell Biology, vol. 11, no. 7, pp. 881–889, 2009.

C. Labbaye and U. Testa, “The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer,” Journal of Hematology & Oncology, vol. 5, article 13, 2012.

L. F. Lu, M. P. Boldin, A. Chaudhry, L. L. Lin, K. D. Taganov, T. Hanada, et al., “Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses,” Cell, vol. 142, no. 6, pp. 914–929, 2010.

W. D. Xu, M. M. Lu, H. F. Pan, and D. Q. Ye, “Association of MicroRNA-146a with autoimmune diseases,” Inflammation, vol. 35, no. 4, pp. 1525–1529, 2012.

S. Roy and C. K. Sen, “MiRNA in innate immune responses: novel players in wound inflammation,” Physiological Genomics, vol. 43, no. 10, pp. 557–565, 2011.

G. Wang, L. S. Tam, E. K. Li, B. C. Kwan, K. M. Chow, C. C. Luk, et al., “Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus,” Journal of Rheumatology, vol. 37, no. 12, pp. 2516–2522, 2010.

A. W. Pedersen, K. Holmstrom, S. S. Jensen, D. Fuchs, S. Rasmussen, P. Kvistborg, et al., “Phenotypic and functional markers for 1alpha, 25-dihydroxyvitamin D(3)-modified regulatory dendritic cells,” Clinical & Experimental Immunology, vol. 157, no. 1, pp. 48–59, 2009.

S. H. Ramkissoon, L. A. Mainwaring, Y. Ogasawara, et al., “Hematopoietic-specific microRNA expression in human cells,” Leukemia Research, vol. 30, no. 5, pp. 643–647, 2006.

C. Urbich, A. Kuehbacher, and S. Dimmeler, “Role of microRNAs in vascular diseases, inflammation, and angiogenesis,” Cardiovascular Research, vol. 79, no. 4, pp. 581–588, 2008.

R. M. O'Connell , D. Kahn, W. S. Gibson, J. L. Round, R. L. Scholz, A. A. Chaudhuri, et al., “MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development,” Immunity, vol. 33, no. 4, pp. 607–619, 2010.

A. Rodriguez, E. Vigorito, S. Clare, M. V. Warren, P. Couttet, D. R. Soond, et al., “Requirement of bic/microRNA-155 for normal immune function,” Science, vol. 316, no. 5824, pp. 608–611, 2007.

H. Zhou, X. Huang, H. Cui, X. Luo, Y. Tang, S. Chen, et al., “miR-155 and its star-form partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells,” Blood, vol. 116, no. 26, pp. 5885–5894, 2010.

Y. Dai, W. Sui, H. Lan, Q. Yan, H. Huang, and Y. Huang, “Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients,” Rheumatology International, vol. 29, no. 7, pp. 749–754, 2009.

Y. Dai, Y. S. Huang, M. Tang, T. Y. Lv, C. X. Hu, Y. H. Tan, et al., “Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients,” Lupus, vol. 16, no. 12, pp. 939–946, 2007.

Y. Liu, “Renal fibrosis: new insights into the pathogenesis and therapeutics,” Kidney International, vol. 69, no. 2, pp. 213–217, 2006.

L. Denby, V. Ramdas, M. W. McBride, J. Wang, H. Robinson, J. McClure, et al., “miR-21 and miR-214 are consistently modulated during renal injury in rodent models,” The American Journal of Pathology, vol. 179, no. 2, pp. 661–672, 2011.

P. A. Gregory, A. G. Bert, E. L. Paterson, S. C. Barry, A. Tsykin, G. Farshid, et al., “The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1,” Nature Cell Biology, vol. 10, no. 5, pp. 593–601, 2008.

O. Ichii, A. Konno, N. Sasaki, D. Endoh, Y. Hashimoto, and Y. Kon, “Autoimmune glomerulonephritis induced in congenic mouse strain carrying telomeric region of chromosome 1 derived from MRL/MpJ,” Histology and Histopathology, vol. 23, no. 4, pp. 411–422, 2008.

O. Ichii, S. Otsuka, N. Sasaki, Y. Namiki, Y. Hashimoto, and Y. Kon, “Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation,” Kidney International, vol. 81, no. 3, pp. 280–292, 2012.

J. Lu, B. C. Kwan, F. M. Lai, L. S. Tam, E. K. Li, K. M. Chow, et al., “Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis,” Nephrology, vol. 17, no. 4, Article ID 222958, pp. 346–351, 2012.

R. W. Chan, F. M. Lai, E. K. Li, L. S. Tam, K. M. Chow, P. K. Li, et al., “Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis,” Rheumatology, vol. 45, no. 8, pp. 951–957, 2006.

Y. Tang, X. Luo, H. Cui, X. Ni, M. Yuan, Y. Guo, et al., “MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins,” Arthritis & Rheumatism, vol. 60, no. 4, pp. 1065–1075, 2009.

X. Luo, W. Yang, D. Q. Ye, H. Cui, Y. Zhang, N. Hirankarn, et al., “A functional variant in microRNA-146a promoter modulates its expression and confers disease risk for systemic lupus erythematosus,” Plos Genetics, vol. 7, no. 6, article e1002128, 2011.

M. C. Lu, N. S. Lai, H. C. Chen, H. C. Yu, K. Y. Huang, C. H. Tung, et al., “Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis,” Clinical & Experimental Immunology, vol. 171, no. 1, Article ID 353010, pp. 91–99, 2013.

X. Zhao, Y. Tang, B. Qu, H. Cui, S. Wang, L. Wang, et al., “MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 62, no. 11, Article ID 205896, pp. 3425–3435, 2010.

K. Takeda and S. Akira, “Toll-like receptors in innate immunity,” International Immunology, vol. 17, no. 1, pp. 1–14, 2005.

F. J. Barrat, T. Meeker, J. Gregorio, J. H. Chan, S. Uematsu, S. Akira, et al., “Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus,” Journal of Experimental Medicine, vol. 202, no. 8, pp. 1131–1139, 2005.

K. McKenna, A.-S. Beignon, and N. Bhardwaj, “Plasmacytoid dendritic cells: linking innate and adaptive immunity,” Journal of Virology, vol. 79, no. 1, pp. 17–27, 2005.

Y. Yuan, S. Kasar, C. Underbayev, D. Vollenweider, E. Salerno, S. V. Kotenko, et al., “Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus,” Molecular Immunology, vol. 52, no. 2, pp. 61–70, 2012.

B. G. Garchow, O. B. Encinas, Y. T. Leung, P. Y. Tsao, R. A. Eisenberg, R. Caricchio, et al., “Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice,” EMBO Molecular Medicine, vol. 3, no. 10, pp. 605–615, 2011.

W. Pan, S. Zhu, M. Yuan et al., “MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1,” Journal of Immunology, vol. 184, no. 12, pp. 6773–6781, 2010.

S. Zhao, Y. Wang, Y. Liang, M. Zhao, H. Long, S. Ding, et al., “MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1,” Arthritis & Rheumatism, vol. 63, no. 5, pp. 1376–1386, 2011.

S. Ding, Y. Liang, M. Zhao, G. Liang, H. Long, S. Zhao, et al., “Decreased microRNA-142-3p/5p expression causes CD4+ T cell activation and B cell hyperstimulation in systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 64, no. 9, Article ID 225496, pp. 2953–2663, 2012.

R. Dai, Y. Zhang, D. Khan et al., “Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus,” Plos one, vol. 5, no. 12, article e14302, 2010.

G. Liu, A. Friggeri, Y. Yang, Y. J. Park, Y. Tsuruta, and E. Abraham, “MiR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage inflammatory responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 37, pp. 15819–15824, 2009.

M. Kurowska-Stolarska, S. Alivernini, L. E. Ballantine, D. L. Asquith, N. L. Millar, D. S. Gilchrist, et al., “MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 27, pp. 11193–11198, 2011.

T. Imaizumi, H. Tanaka, A. Tajima et al., “IFN-γ and TNF-α synergistically induce microRNA-155 which regulates TAB2/IP-10 expression in human mesangial cells,” The American Journal of Nephrology, vol. 32, no. 5, pp. 462–468, 2010.

A. Kashem, M. Endoh, N. Yano, F. Yamauchi, Y. Nomoto, and H. Sakai, “Expression of inducible-NOS in human glomerulonephritis: the possible source is infiltrating monocytes/macrophages,” Kidney International, vol. 50, no. 2, pp. 392–399, 1996.

C. M. Reilly, J. C. Oates, J. A. Cook, J. D. Morrow, P. V. Halushka, and G. S. Gilkeson, “Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-γ agonists,” Journal of Immunology, vol. 164, no. 3, pp. 1498–1504, 2000.

S. M. Ka, C. W. Cheng, H. A. Shui, W. M. Wu, D. M. Chang, Y. C. Lin, et al., “Mesangial cells of lupus-prone mice are sensitive to chemokine production,” Arthritis Research & Therapy, vol. 9, no. 4, article R67, 2007.

D. Y. Ma and E. A. Clark, “The role of CD40 and CD154/CD40L in dendritic cells,” Seminars in Immunology, vol. 21, no. 5, pp. 265–272, 2009.

O. Jin, S. Kavikondala, M. Y. Mok, L. Sun, J. Gu, R. Fu, et al., “Abnormalities in circulating plasmacytoid dendritic cells in patients with systemic lupus erythematosus,” Arthritis Research & Therapy, vol. 12, no. 4, article R137, 2010.

A. Henriques, L. Ines, T. Carvalheiro, M. Couto, A. Andrade, S. Pedreiro, et al., “Functional characterization of peripheral blood dendritic cells and monocytes in systemic lupus erythematosus,” Rheumatology International, no. 4, pp. 863–869, 2012.

L. Ronnblom, “Potential role of IFNalpha in adult lupus,” Arthritis Research & Therapy, vol. 12, supplement 1, article S3, 2010.

V. N. Kim, “MicroRNA biogenesis: coordinated cropping and dicing,” Nature Reviews Molecular Cell Biology, vol. 6, no. 5, pp. 376–385, 2005.

S. A. Muljo, K. M. Ansel, C. Kanellopoulou, D. M. Livingston, A. Rao, and K. Rajewsky, “Aberrant T cell differentiation in the absence of Dicer,” The Journal of Experimental Medicine, vol. 202, no. 2, Article ID 160097, pp. 261–269, 2005.

S. B. Koralov, S. A. Muljo, G. R. Galler et al., “Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage,” Cell, vol. 132, no. 5, pp. 860–874, 2008.

H. Wu, J. R. Neilson, P. Kumar, M. Manocha, P. Shankar, P. A. Sharp, et al., “miRNA profiling of naive, effector and memory CD8 T cells,” Plos One, vol. 2, no. 10, article e1020, 2007.

C. Deng, Q. Lu, Z. Zhang, T. Rao, J. Attwood, R. Yung, et al., “Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling,” Arthritis & Rheumatism, vol. 48, no. 3, pp. 746–756, 2003.

Q. Yang, Z. Jie, H. Cao et al., “Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C,” Carcinogenesis, vol. 32, no. 5, pp. 713–722, 2011.

M. Wang, Y. Hu, M. D. Amatangelo, and M. E. Stearns, “Role of ribosomal protein RPS2 in controlling let-7a expression in human prostate cancer,” Molecular Cancer Research, vol. 9, no. 1, Article ID 211480, pp. 36–50, 2011.

C. de Vito, N. Riggi, M. L. Suva, M. Janiszewska, J. Horlbeck, K. Baumer, et al., “Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development,” Plos One, vol. 6, no. 8, article e23592, 2011.

S. J. Kim, J. Y. Shin, K. D. Lee, Y. K. Bae, K. W. Sung, S. J. Nam, et al., “MicroRNA let-7a suppresses breast cancer cell migration and invasion through downregulation of C-C chemokine receptor type 7,” Breast Cancer Research, vol. 14, no. 1, article R14, 2012.

Y. Wang, X. Hu, J. Greshock, L. Shen, X. Yang, Z. Shao, et al., “Genomic DNA copy-number alterations of the let-7 family in human cancers,” Plos One, vol. 7, no. 9, article e44399, 2012.

A. Esquela-Kerscher, P. Trang, J. F. Wiggins et al., “The let-7 microRNA reduces tumor growth in mouse models of lung cancer,” Cell Cycle, vol. 7, no. 6, pp. 759–764, 2008.

Y. Zhu, Z. Zhong, and Z. Liu, “Lentiviral vector-mediated upregulation of let-7a inhibits gastric carcinoma cell growth in vitro and in vivo,” Scandinavian Journal of Gastroenterology, vol. 46, no. 1, pp. 53–59, 2011.

G. Wang, L. S. Tam, B. C. Kwan, E. K. Li, K. M. Chow, C. C. Luk, et al., “Expression of miR-146a and miR-155 in the urinary sediment of systemic lupus erythematosus,” Clinical Rheumatology, vol. 31, no. 3, pp. 435–440, 2012.

A. Ceribelli, B. Yao, P. R. Dominguez-Gutierrez, M. A. Nahid, M. Satoh, and E. K. Chan, “MicroRNAs in systemic rheumatic diseases,” Arthritis Research & Therapy, vol. 13, no. 4, article 229, 2011.

E. K. O. Ng, W. W. S. Chong, H. Jin et al., “Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening,” Gut, vol. 58, no. 10, pp. 1375–1381, 2009.

A. J. Schetter, N. H. Heegaard, and C. C. Harris, “Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways,” Carcinogenesis, vol. 31, no. 1, pp. 37–49, 2010.

J. Wittmann and H. M. Jack, “Serum microRNAs as powerful cancer biomarkers,” Biochimica et Biophysica Acta, vol. 1806, no. 2, pp. 200–207, 2010.

E. Tili, J.-J. Michaille, V. Gandhi, W. Plunkett, D. Sampath, and G. A. Calin, “miRNAs and their potential for use against cancer and other diseases,” Future Oncology, vol. 3, no. 5, pp. 521–537, 2007.

J. Elmen, M. Lindow, S. Schutz, M. Lawrence, A. Petri, S. Obad, et al., “LNA-mediated microRNA silencing in non-human primates,” Nature, vol. 452, no. 7189, pp. 896–899, 2008.

K. M. Pauley, S. Cha, and E. K. Chan, “MicroRNA in autoimmunity and autoimmune diseases,” Journal of Autoimmunity, vol. 32, no. 3-4, pp. 189–194, 2009.

W. Hai-yan, L. Yang, C. Mei-hong, and Z. Hui, “Expression of MicroRNA-146a in peripheral blood mononuclear cells in patients with systemic lupus Erythematosus,” Acta Academiae Medicinae Sinicae, vol. 33, no. 2, pp. 185–188, 2011.

Y. Pan, T. Jia, Y. Zhang, K. Zhang, R. Zhang, J. Li, et al., “MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice,” International Journal of Nanomedicine, vol. 7, pp. 5957–5967, 2012.

A. S. Hartner, F. Pröls, U. Müller, and R. B. Sterzel, “Alpha8 integrin in glomerular mesangial cells and in experimental glomerulonephritis,” Kidney International, vol. 56, no. 4, pp. 1468–1480, 1999.

Y. Scindia, U. Deshmukh, P.-R. Thimmalapura, and H. Bagavant, “Anti-α8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 58, no. 12, pp. 3884–3891, 2008.

A. L. Bierly, W. J. Shufesky, W. Sukhumavasi, A. E. Morelli, and E. Y. Denkers, “Dendritic cells expressing plasmacytoid marker PDCA-1 are Trojan horses during Toxoplasma gondii infection,” Journal of Immunology, vol. 181, no. 12, pp. 8485–8491, 2008.

S. Monticelli, K. M. Ansel, C. Xiao, N. D. Socci, A. M. Krichevsky, T. H. Thai, et al., “MicroRNA profiling of the murine hematopoietic system,” Genome Biology, vol. 6, no. 8, article R71, 2005.

D. Y. M. Leung and J. W. Bloom, “Update on glucocorticoid action and resistance,” Journal of Allergy and Clinical Immunology, vol. 111, no. 1, pp. 3–22, 2003.

R. W. J. Lee, T. J. Creed, L. P. Schewitz et al., “CD4+CD25(int) T cells in inflammatory diseases refractory to treatment with glucocorticoids,” Journal of Immunology, vol. 179, no. 11, pp. 7941–7948, 2007.

L. Lu, P. Schwartz, L. Scarampi et al., “MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management,” Gynecologic Oncology, vol. 122, no. 2, pp. 366–371, 2011.

S. Polikepahad, J. M. Knight, A. O. Naghavi, T. Oplt, C. J. Creighton, C. Shaw, et al., “Proinflammatory role for let-7 microRNAS in experimental asthma,” Journal of Biological Chemistry, vol. 285, no. 39, pp. 30139–30149, 2010.